Page 269 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 269
P0857 98% SVR12 IN KOREAN AND TAIWANESE PATIENTS WITH ePOSTERS
CHRONIC GENOTYPE 1 HCV INFECTION RECEIVING 12
P0858 WEEKS OF LEDIPASVIR/SOFOSBUVIR: RESULTS FROM AN
P0859 INTERNATIONAL, MULTICENTER PHASE 3 STUDY
P0860 Young-Suk Lim*, Wan-Long Chuang, Sang-Hoon Ahn, Cheng-
P0861 Yuan Peng, Seung-Woon Paik, Rong-Nan Chien, Chi-Jen Chu,
P0862 Jenny C. Yang, Hongmei Mo, Bing Gao, Phillip S. Pang, Steven J. Knox,
John G. McHutchison,Youn-Jae Lee, Ting-Tsung Chang, Sook-
Hyang Jeong, Kwang-Hyub Han, Jia-Horng Kao, South Korea
EARLY HCV RNA DECLINE BY BASELINE
CHARACTERISTICS IN HCV INFECTED PATIENTS
RECEIVING SOFOSBUVIR-BASED TREATMENT: AN
ITALIAN SINGLE CENTER EXPERIENCE
Alessandra Mangia*, Valeria Piazzolla, Rosanna Santoro,
Leonardo Mottola, Daniela Petruzzellis, Maria Ripoli, Francesco Leone,
Domenico Facciorusso, Italy
GENOTYPE 1 AND 4 CIRRHOTICS: WHAT IS THE SVR
RATE IN COMMUNITY CLINICS USING SIMEPREVIR AND
SOFOSBUVIR?
Anna Marie Hefner*, Idrees Suliman, Roukaya Hassanein, Catherine Hill,
Renee Pozza, Thomas A. Couturier, Preeti A. Reshamwala,
Tarek I. Hassanein, The United States
THE IMPACT OF INTERFERON-FREE REGIMENS ON
EMPLOYMENT RATE DURING TREATMENT IN PATIENTS
WITH CHRONIC HEPATITIS C
Blaise Kutala*, Feryel Mourri, Nathalie Boyer, Corinne Castelnau,
Veronique Sitruk, Nathalie Giuily,Tarik Asselah, Patrick Marcellin, France
EVALUATION OF THE PAN-GENOTYPIC HCV NS3/4A
PROTEASE INHIBITOR GS-9857 IN HEALTHY VOLUNTEERS
Brian Kirby*, Jenny Yang, Chris Yang, Qinghua Song,Yi Wang,
James Taylor, Luisa Stamm, Anita Mathias, The United States
FIRST REAL CLINICAL PRACTICE DATA ON SOFOSBUVIR,
SIMEPREVIR AND DACLATASVIR WITH HCV-CHRONICALLY
INFECTED PATIENTS IN SPAIN: THE HEPATIC REGISTRY
EXPERIENCE
Carlos Fernández-Carrillo*, Juan Manuel Pascasio, Sabela Lens,
Carmen Vinaixa, Enrique Fraga, María Buti, Manuel Romero-Gómez,
Javier García-Samaniego, Javier Crespo, Diego Rincón, José Luis Calleja, Spain
Vienna, Austria • April 22–26, 2015 269
CHRONIC GENOTYPE 1 HCV INFECTION RECEIVING 12
P0858 WEEKS OF LEDIPASVIR/SOFOSBUVIR: RESULTS FROM AN
P0859 INTERNATIONAL, MULTICENTER PHASE 3 STUDY
P0860 Young-Suk Lim*, Wan-Long Chuang, Sang-Hoon Ahn, Cheng-
P0861 Yuan Peng, Seung-Woon Paik, Rong-Nan Chien, Chi-Jen Chu,
P0862 Jenny C. Yang, Hongmei Mo, Bing Gao, Phillip S. Pang, Steven J. Knox,
John G. McHutchison,Youn-Jae Lee, Ting-Tsung Chang, Sook-
Hyang Jeong, Kwang-Hyub Han, Jia-Horng Kao, South Korea
EARLY HCV RNA DECLINE BY BASELINE
CHARACTERISTICS IN HCV INFECTED PATIENTS
RECEIVING SOFOSBUVIR-BASED TREATMENT: AN
ITALIAN SINGLE CENTER EXPERIENCE
Alessandra Mangia*, Valeria Piazzolla, Rosanna Santoro,
Leonardo Mottola, Daniela Petruzzellis, Maria Ripoli, Francesco Leone,
Domenico Facciorusso, Italy
GENOTYPE 1 AND 4 CIRRHOTICS: WHAT IS THE SVR
RATE IN COMMUNITY CLINICS USING SIMEPREVIR AND
SOFOSBUVIR?
Anna Marie Hefner*, Idrees Suliman, Roukaya Hassanein, Catherine Hill,
Renee Pozza, Thomas A. Couturier, Preeti A. Reshamwala,
Tarek I. Hassanein, The United States
THE IMPACT OF INTERFERON-FREE REGIMENS ON
EMPLOYMENT RATE DURING TREATMENT IN PATIENTS
WITH CHRONIC HEPATITIS C
Blaise Kutala*, Feryel Mourri, Nathalie Boyer, Corinne Castelnau,
Veronique Sitruk, Nathalie Giuily,Tarik Asselah, Patrick Marcellin, France
EVALUATION OF THE PAN-GENOTYPIC HCV NS3/4A
PROTEASE INHIBITOR GS-9857 IN HEALTHY VOLUNTEERS
Brian Kirby*, Jenny Yang, Chris Yang, Qinghua Song,Yi Wang,
James Taylor, Luisa Stamm, Anita Mathias, The United States
FIRST REAL CLINICAL PRACTICE DATA ON SOFOSBUVIR,
SIMEPREVIR AND DACLATASVIR WITH HCV-CHRONICALLY
INFECTED PATIENTS IN SPAIN: THE HEPATIC REGISTRY
EXPERIENCE
Carlos Fernández-Carrillo*, Juan Manuel Pascasio, Sabela Lens,
Carmen Vinaixa, Enrique Fraga, María Buti, Manuel Romero-Gómez,
Javier García-Samaniego, Javier Crespo, Diego Rincón, José Luis Calleja, Spain
Vienna, Austria • April 22–26, 2015 269
